Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company…
News
Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023
AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for…
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 – SAN FRANCISCO,…
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader…
Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer
Ms. Yañez brings deep category experience and will lead Aerami’s focus on cardiopulmonary disease as…
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
– Conference call and webcast to be held on Monday, January 9, 2023 at 1:30…
Akadeum Life Sciences Launches First of its Kind Product Benefitting Cell and Gene Therapy Research Following Successful Data from Early Access Program
Positive Results Spurs Launch of Akadeum’s Leukopak Isolation Kit citing speed, scalability, and cell recovery…
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences,…
Universe Pharmaceuticals INC Announces Inclusion of Six Products into the First Edition of Catalogue of Medicine for Patients Infected with COVID-19
Ji’an, Jiangxi, China, Dec. 21, 2022 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq:…
Motus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests
Pre-clinical tests show enhanced functionality of Pure-Vu EVS that can enable physicians to overcome common…
Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors
BALTIMORE, Dec. 21, 2022 (GLOBE NEWSWIRE) — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused…
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
Achiko AG Production and Sales Update
AptameX™ Gen 2 Covid-19 rapid calibration outperforms Abbott Pan Bio and Clugene’s rapid tests in…
AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine
– Topline data expected to be announced in 2H 2023 – – Topline data from…
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate…
TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference
MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical…
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic”…
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple…
Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
– The global THRIVE Phase 3 trial will be conducted in approximately 50 centers across…
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Media Release COPENHAGEN, Denmark; December 21, 2022 JNDA submission supported by results of Japanese and…